Genetically modified cells expressing a TGF beta inhibitor, the cells being lung cancer cells
AssigneeNovaRx
InventorHabib Fakhrai
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions comprising a therapeutically effective amount of genetically modified cells containing a genetic construct expressing a TGFβ inhibitor effective to reduce expression of TGFβ, where the genetically modified cells are non-small cell lung cancer (NSCLC) cells or small cell lung cancer (SCLC) cells, and related methods.
Claims16
An isolated composition for prolonging survival of a subject having a lung cancer, said composition comprising a therapeutically effective amount of genetically modified cells, wherein said modification comprises a genetic construct that produces antisense nucleic acid molecules that inhibit production of TGFβ in said cells,
- wherein said genetically modified cells are non-small cell lung cancer (NSCLC) cells, or small cell lung cancer (SCLC) cells, and wherein said cells are autologous or allogenic to said subject.
A method for prolonging survival of a subject having a lung cancer comprising the step of administering to said subject a composition comprising a therapeutically effective amount of genetically modified cells, wherein said modification comprises a genetic construct that produces antisense nucleic acid molecules that inhibit production of TGFβ in said cells,
- wherein said genetically modified cells non-small cell lung cancer (NSCLC) cells, or small cell lung cancer (SCLC) cells, and wherein said cells are autologous or allogenic to said subject.
Dependencies are inferred from the claim text.